Bayer's Monsanto to pay $160 mln to resolve Seattle's PCB contamination lawsuit
By Jonathan Stempel
July 25 (Reuters) -Monsanto will pay $160 million to settle a lawsuit by the city of Seattle that accused the unit of Germany's Bayer BAYGn.DE of polluting the city's drainage system and the local Lower Duwamish River with toxic chemicals known as PCBs.
City Attorney Ann Davison announced the settlement on Thursday, calling it the largest for a single city over PCBpollution.
In a statement, Monsanto said it will pay $35 million for PCB remediation, and $125 million to address other Seattle claims. The company did not admit liability or wrongdoing.
Seattle accused Monsanto of creating a public nuisance by selling polychlorinated biphenyls for commercial use from 1935 to 1977 despite knowing they polluted the environment, harming people and wildlife.
The city said PCBs remained over the years in exterior paint and caulk on buildings, and resulted in contaminated stormwater flowing into the river.
Seattle sued Monsanto in January 2016. The settlement averts a scheduled Sept. 23 trial in that city's federal court.
Monsanto said in an August 2022 filing that Seattle had been seeking nearly $750 million.
The company reached a separate $95 million settlement with Washington state in June 2020 over PCB contamination.
PCBs were outlawed by the U.S. government in 1979, and have been linked to cancer, immune system and other health problems.
Monsanto was the only U.S. maker of PCBs. It has said it stopped making them because they were not readily biodegradable.
In November 2022, Monsanto won court approval for a $650 million settlement with a class of 2,500 local governments over PCB contamination in various waters.
Other governments chose to sue Monsanto individually. Monsanto said nine cases remain pending, and that it is committed to defending itself at trial unless it settles.
Bayer bought Monsanto for $63 billion in 2018. It has also faced extensive and costly litigation over whether Monsanto's Roundup weed killer causes cancer.
The case is Seattle v. Monsanto Co et al, U.S. District Court, Western District of Washington, No. 16-00107.
Reporting by Jonathan Stempel in New York; editing by Diane Craft
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
